Skip to main content
Premium Trial:

Request an Annual Quote

BARDA Awards $51.9M to DNAe to Develop Rapid Diagnostics

NEW YORK (GenomeWeb) – The US Department of Health and Human Services' Biomedical Advanced Research and Development Authority has awarded a $51.9 million contract to London-based DNA Electronics to develop semiconductor-based next-generation sequencing diagnostics for antimicrobial resistant infections and influenza, the company said today.

Under the auspices of the project, entitled Pathogen Identification from Specimen via Capture Extraction and Sequencing, DNAe will complete development and validation of its Genalysis platform. It will also submit its tests for US Food and Drug Administration clearance.

"Unlike existing sequencing devices, the platform operates 'push button' directly from raw clinical specimens such as blood or swabs, delivering a clinically-relevant report for the physician," Sam Reed, president of DNAe's US office, said in a statement. Users do not have to be specially trained in sequencing, Reed added, "enabling [the platform] to be used in a wide range of near-to-patient clinical environments."

The company's first product will be a diagnostic test for sepsis. DNAe said the test is in late stage development and testing and will launch in 2018.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more